Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PKLR | P30613 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2426656 | 1.00 | CACNA1B (0.59) | CACNA1BGAAHPGDHTTPKM | |
| SCHEMBL66715 | 1.00 | CACNA1B (0.59) | CACNA1BGAAHPGDHTTPKM | |
| SCHEMBL2452773 | 1.00 | CACNA1B (0.59) | CACNA1BGAAHPGDHTTPKM | |
| SCHEMBL16497782 | 1.00 | CACNA1B (0.59) | CACNA1BGAAHPGDHTTPKM | |
| SCHEMBL66682 | 0.85 | CACNA1B (0.57) | CACNA1BGAAHSD11B1L3MBTL1 | |
| SCHEMBL67385 | 0.85 | CACNA1B (0.57) | CACNA1BGAAHSD11B1L3MBTL1 | |
| SCHEMBL2419370 | 0.85 | CACNA1B (0.57) | CACNA1BGAAHSD11B1L3MBTL1 | |
| SCHEMBL16497951 | 0.85 | CACNA1B (0.57) | CACNA1BGAAHSD11B1L3MBTL1 | |
| SCHEMBL2422009 | 0.80 | CACNA1B (0.72) | CACNA1BHTTCNR1LMNA | |
| SCHEMBL2454259 | 0.79 | TRPV4 (0.47) | CACNA1BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2367790-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010062927-A2 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CACNA1B 5/4885GAA 2205/4885HPGD 1353/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CACNA1B 5/4885GAA 2205/4885HPGD 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.